Industry Insights Seminar Series

• 12.00 -1.00 pm
• In person and online
• In person at Institute of Developmental & Regenerative Medicine (IDRM), Old Road Campus, Headington, OX3 7TY
• Networking & 1:1 meeting opportunities

The Industry Insight Seminars provide the opportunity for Oxford scientists to attend a scientific seminar of interest and to network with industry scientists. Selected industry speakers provide seminars that are scientific in nature, across a range of medical or health topics.  Speakers are encouraged to bring along colleagues to facilitate networking; one to one meetings can be facilitated upon request.  Seminars are suitable for all scientists with some knowledge or interest in each topic area, from PhD students to PIs.  Although mostly aimed at an academic audience, those located in the BioEscalator and Wood Centre, as well as local spinouts, are welcome to attend. 

Please contact Sheena Lee if you have any questions or have an industry partner you would like to invite to speak

10th October 2024:   The impacts of omics data on translational science

Presenter: Dr Thomas Freeman (Senior Director, Translational Systems Immunology)

Company: Johnson & Johnson Innovative Medicine

Speaker profile: Prior to joining Johnson and Johnson Innovative Medicine in June 2020, Tom Freeman had a long academic career working in different areas of innate functional genomics, immunity and computational biology. He held the chair of Systems Immunology at the University of Edinburgh and before this led Gene Expression Group at the Sanger Institute (1994-2000) before joining the MRC HGMP-Resource Centre (2000-2005), also on the Hinxton Campus, where he headed up the UK National Microarray Programme.

 His interest in data analysis and generating expression atlases led to him to develop a number of well-known network analysis tools and approaches. He has founded two companies in the data analytics space and authored over 160 peer-reviewed articles. Tom is now a Senior Director at Johnson and Johnson Innovative Medicine, where he heads the Translational Systems Immunology Group which is focused on delivering portfolio-facing computation analyses in support of patient stratification, biomarker identification, analysis of clinical trials data and delivering precision medicine.

Register by clicking on the following link: Registration 

5th December 2024: Title TBA

Presenter: Kuldeep Singh (Chief Business Officer)

Company: Softude

Description: Softude delivers digital breakthroughs to transform healthcare. They engage patients, practitioners, and hospital administrators with relevant and meaningful data to inform and advise.  They work in the fields of AI/ML, Mobile app development, Digital transformation, product engineering, Home Healthcare Management Solutions, Health and Wellness Apps, Telemedicine, Hospital Information System

Registration: here

2024

Professor Nadeem Sarwar  - Novo Nordisk - Prevention is better than cure – realising a sustainable new paradigm to predict and pre-empt obesity and its consequences

Nicholas Zoulias - Azenta - Harnessing the power of multiomics from a single sample to explore tumor heterogeneity and advancing immuno-oncology

Dr Shea Hamilton - Somalogic - The transformative role of Somascan for protein biomarker discovery, validation and translation

Dr Sarantis Chlamydas – Olink - Precision proteomics broadens MultiOmics repertoire and enables biomarker discovery

Christel Iffland, Chris Birchall - OmniAb-Opening the Barn Door to Antibody Discovery with OmniAb

Jayne Wallace - Oxford Nanopore - Democratising sequencing: Latest from Oxford Nanopore Technologies

Luke Devey – Quell - Restoring the balance with Regulatory T Cell Therapies/ Opportunities and Challenges in Biotech, 2024

2023

Balaji Modhagala, Subhagata Chattopadhyay – SquareML - AI-ML in Healthcare: Predicting 30-day Post-discharge Unplanned Readmission Risks in the Elderly - a Use Case

Casper Wilstrup – Abzu - Augmenting Drug Discovery with AI

Quin Wills - Ochre Bio - Maintaining Human Livers Outside of the Body

Jo Howson - Novo Nordisk - Genetics and Drug Discovery

onathan Kwok – Infinitopes - UK positioning as a cancer vaccine superpower- hyperbole or reality? Infinitopes as a CRUK-led cancer vaccine spinout from the Oxford ecosystem

Lisa Caproni - Touchlight - The Making of DNA:  The role of enzymatic doggybone DNA in enabling future genetic medicines

Daniel Tomé, Mariana Fontes – Olink - Understanding human disease in the post-genomics era

Hussein - Al-Mossawi – AstraZeneca - Targeting type 1 IFN in immune-mediated inflammatory disease

2022

Iris-Valerie Stracke – Psious - Virtual reality and mental health

William Drewe, Martin Main - Medicines Discovery Catapult - Advancing UK Medicines Discovery through Innovative Partnerships

Jack Pearson - Natural Cycles - Natural Cycles: Revolutionising research in Women's Health

Jason Crain – IBM - Physical modelling and machine intelligence for accelerated discovery

Yatish Lad - Oxford BioMedica - Gene therapy – coming of age

Martin-Immanuel Bittner – Arctoris - Combining robotics and AI: the emergence of data-driven drug discovery

Anna Hakes – BridgeBio - Bridgebio Pharma: turning translational academic research into medicines for patients with genetic diseases

2021

Ramneek Gupta - Novo Nordisk Research Centre Oxford - Target Discovery Opportunities using Machine Learning on Longitudinal Patient Journeys

Anjan Thakurta – BMS- Translational Fellowships: Perspectives from a BMS mentor and 5 Oxford fellows 

David Price -Vertex - Humanising drugs

Katharina Duerr - OMass - Development of Novel Medicines using high resolution native mass spectrometry of intact protein assemblies

Dr Manuela Zonca – PsiOxus - Tumour re-engineering

Joanna Gould – VisusNano - Novel drug-delivery in ophthalmology

Jane Osbourn, Paul Kellam – BIA - Accelerating Covid-19 Antibody Discovery Through Industry-Academia Consortium

Joe Fitchett - Mologic     - Transforming the path for equitable access to rapid diagnostics for epidemics

Ilona Gutcher – Bayer - Targeting the Aryl Hydrocarbon Receptor (AHR) as a novel immunotherapy for the treatment of cancer

David Lowe – Evox - Exosome-Based Therapies for the Treatment of Rare Genetic Diseases